Incidence and influencing factors associated with exit site infections in temporary catheters for hemodialysis and apheresis.

UNLABELLED: The authors examined the incidence and influencing actors of exit site infections (ESIs) in patients using dual and triple lumen dialysis catheters. The prospective, randomized study was conducted at 11 centers. Data were analyzed on 473 patients randomized to receive 235 dual lumen catheters (DLCs) or 238 triple lumen catheters (TLCs). RESULTS: ESIs occurred in 10 patients (2.1%). The number of intertreat-ment uses (p = 0.006), total number of uses (p = 0.009), and catheter placement duration (p = 0.03) were significantly associated with incidence of ESI in both treatment groups. Although patients with TLCs had a significantly higher inter-treatment use than patients with DLCs (p = .04), no sgnificant difference in the incidence of ESI was found (p = 0.11). Diabetic status and catheter insertion site were not found to be significantly related to ESI ( p= 0.09 and p = 0.54, respectively), although a trend toward significance was noted for diabetic status. CONCLUSIONS: Stringent exit site care by specially trained staff and shorter catheter duration most likely contributed to the low incidence of ESIs. Other influencing factors included numbers of inter-treatment uses, total number of uses, and catheter placement duration.

A multicenter, prospective, randomized, comparative evaluation of dual- versus triple-lumen catheters for hemodialysis and apheresis in 485 patients.

BACKGROUND: The purpose of this study is to compare a new temporary triple-lumen catheter (TLC) for dialysis that has a third lumen devoted to fluid and medication administration or blood sampling with a marketed dual-lumen catheter (DLC). METHODS: Four hundred eighty-five patients referred for acute hemodialysis or apheresis were randomly assigned to either a TLC or DLC in a multicenter, prospective, randomized trial. RESULTS: Analysis of blood flow rates was completed on 464 patients (228 patients, DLC; 236 patients, TLC) with a total of 1,681 hemodialysis (808 treatments, DLC; 873 treatments, TLC) and 82 apheresis treatments (37 treatments, DLC; 45 treatments, TLC). During hemodialysis, a median achieved flow rate (AFR) of 267 mL/min was realized for both groups (P = 0.58). During apheresis, a median AFR of 72.5 mL/min (range, 50 to 150 mL/min) was achieved in the DLC group, and 87 mL/min (range, 60 to 150 mL/min), in the TLC group (P = 0.14). Three hundred ninety-three patients (193 patients, DLC; 200 patients, TLC) had blood and catheter tip cultures performed on removal, and catheter-related bloodstream infection (CRBSI) status was determined. Thirty-one patients (7.9%) had a CRBSI: 16 patients (8.3%), DLC; and 15 patients (7.5%), TLC (P= 0.77). Incidence densities of CRBSI were 12.4/1,000 DLC-days and 10.2/1,000 TLC-days (P = 0.59). The CRBSI incidence of 18.2/1,000 catheter-days for femoral sites was significantly greater than the 7/1,000 catheter-days for jugular sites (P = 0.02) and 6.6/1,000 catheter-days for combined jugular and subclavian sites (P = 0.01). In multivariate analysis, antibiotic use was the only factor related to CRBSI (odds ratio, 0.30; 95% confidence interval, 0.12 to 0.76). There were no statistically significant differences in rates of other complications between the 2 catheters. CONCLUSION: Results show that the new TLC is similar to the marketed DLC.